hydroxyurea has been researched along with Hypereosinophilic Syndrome in 47 studies
Hypereosinophilic Syndrome: A heterogeneous group of disorders with the common feature of prolonged eosinophilia of unknown cause and associated organ system dysfunction, including the heart, central nervous system, kidneys, lungs, gastrointestinal tract, and skin. There is a massive increase in the number of EOSINOPHILS in the blood, mimicking leukemia, and extensive eosinophilic infiltration of the various organs.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The combination of IFN-alpha and hydroxyurea is very useful and allows dosage reduction of IFN-alpha and better control of hypereosinophilia than with either agent alone." | 2.43 | Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis. ( Butterfield, JH, 2005) |
| "We report four Arab patients with idiopathic hypereosinophilic syndrome (IHES)." | 2.41 | Idiopathic hypereosinophilic syndrome: a report of four cases in Arabs, and a review of the literature. ( Abdelaal, MA; Gangi, MT; George, BO; Kinsara, AJ, 2001) |
| "Cardiac tamponade is a rare but serious complication of IHES." | 1.35 | Cardiac tamponade: a rare complication of idiopathic hypereosinophilic syndrome. ( Ahmed, S; Duncan, B; Fernandez, AB; Firshein, S; Kluger, J, 2009) |
| "We report a rare case of eosinophilic leukemia transformation in a patient with polycythemia rubra vera on hydroxycarbamide (hydroxyurea) therapy only." | 1.33 | Eosinophilic leukemic transformation in polycythemia rubra vera (PRV). ( Chim, CS; Ma, SK, 2005) |
| "Idiopathic hypereosinophilic syndrome is a rare condition characterized by extremely high peripheral blood eosinophil counts." | 1.33 | Factor V Leiden mutation and deep venous thrombosis in a patient with hypereosinophilic syndrome. ( Aslan, V; Entok, E, 2006) |
| "The hypereosinophilic syndrome is a multi-organ disease characterized by large counts of eosinophils in peripheral blood observed during at least six months without any evidence for other known causes of eosinophilia." | 1.33 | [The hypereosinophilic syndrome: case report]. ( Grzybowski, G; Mikołajczyk, K; Samborski, W; Walkowiak, B; Zaba, R, 2006) |
| "Giant cell arteritis is a T-cell dependent auto-immune vasculitis that involves a T-helper l (Th1) cell response." | 1.31 | [Horton's disease and hypereosinophilic syndrome: a non-fortuitous association]. ( Gissot, V; Jauberteau, MO; Liozon, E; Loustaud, V; Soria, P; Vidal, E, 2000) |
| "Hypereosinophilic syndrome was diagnosed." | 1.31 | Successful treatment of hypereosinophilic syndrome in a dog. ( Perkins, M; Watson, A, 2001) |
| " The dosage schedule was governed by the clinical and echocardiographic findings." | 1.30 | [Löffler's parietal fibroplastic endocarditis. Echocardiographic course over 5 years]. ( Braun, B; Günther, E; Hust, MH; Metzler, B; Perier, P, 1997) |
| "One of our patients developed the adult respiratory distress syndrome thought to be a complication of the HES." | 1.29 | Pulmonary involvement in the hypereosinophilic syndrome. ( Kollef, MH; Meyer, JI; Winn, RE, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (21.28) | 18.2507 |
| 2000's | 24 (51.06) | 29.6817 |
| 2010's | 12 (25.53) | 24.3611 |
| 2020's | 1 (2.13) | 2.80 |
| Authors | Studies |
|---|---|
| Iurlo, A | 1 |
| Cattaneo, D | 1 |
| Gianelli, U | 1 |
| Groh, M | 1 |
| Lefèvre, G | 1 |
| Ackermann, F | 1 |
| Étienne, N | 1 |
| Kahn, JE | 2 |
| Williams, AK | 1 |
| Dou, C | 1 |
| Chen, LYC | 1 |
| Andersen, C | 1 |
| Yadav, H | 1 |
| Iyer, VN | 1 |
| Rider, TG | 1 |
| George, SMC | 1 |
| Batool, A | 1 |
| Tidbury, HL | 1 |
| Grace, RJ | 1 |
| Newman, JA | 1 |
| Ali, Z | 1 |
| Felton, JR | 1 |
| Kim, JA | 1 |
| Kim, N | 1 |
| Choi, HS | 1 |
| Choung, HK | 1 |
| Khwarg, SI | 1 |
| Gotlib, J | 1 |
| Roufosse, F | 3 |
| Takeuchi, Y | 1 |
| Matsuura, S | 1 |
| Fujino, Y | 1 |
| Nakajima, M | 1 |
| Takahashi, M | 1 |
| Nakashima, K | 1 |
| Sakai, Y | 1 |
| Uetsuka, K | 1 |
| Ohno, K | 1 |
| Nakayama, H | 1 |
| Tsujimoto, H | 1 |
| Cocker, MS | 1 |
| Abdel-Aty, H | 1 |
| Alakija, P | 1 |
| Strohm, O | 1 |
| Friedrich, MG | 1 |
| Butterfield, JH | 5 |
| Fernandez, AB | 1 |
| Ahmed, S | 1 |
| Duncan, B | 1 |
| Firshein, S | 1 |
| Kluger, J | 1 |
| Ogbogu, PU | 1 |
| Bochner, BS | 1 |
| Gleich, GJ | 1 |
| Huss-Marp, J | 1 |
| Leiferman, KM | 1 |
| Nutman, TB | 1 |
| Pfab, F | 1 |
| Ring, J | 1 |
| Rothenberg, ME | 1 |
| Sajous, MH | 1 |
| Sheikh, J | 1 |
| Simon, D | 1 |
| Simon, HU | 1 |
| Stein, ML | 1 |
| Wardlaw, A | 1 |
| Weller, PF | 1 |
| Klion, AD | 1 |
| Srinivasan, A | 1 |
| Lavanya, R | 1 |
| Sankar, J | 1 |
| Prochorec-Sobieszek, M | 1 |
| Nasiłowska-Adamska, B | 1 |
| Borg, K | 1 |
| Kopeć, I | 1 |
| Kos-Zakrzewska, K | 1 |
| Juszczyński, P | 1 |
| Warzocha, K | 1 |
| Weiler, CR | 1 |
| Kanthila, J | 1 |
| Bhaskaranand, N | 1 |
| Cogan, E | 1 |
| Ault, P | 1 |
| Cortes, J | 1 |
| Koller, C | 1 |
| Kaled, ES | 1 |
| Kantarjian, H | 1 |
| George, BO | 1 |
| Abdelaal, MA | 1 |
| Gangi, MT | 1 |
| Kinsara, AJ | 1 |
| Chim, CS | 1 |
| Ma, SK | 1 |
| Borbényi, Z | 1 |
| Vogler, S | 1 |
| Burkhard, R | 1 |
| Florian, S | 1 |
| Esterbauer, H | 1 |
| Binder, T | 1 |
| Müllauer, L | 1 |
| Haas, OA | 1 |
| Sperr, WR | 1 |
| Sillaber, C | 1 |
| Valent, P | 1 |
| van Ruth, S | 1 |
| Lokhorst, HM | 1 |
| Bruijnzeel-Koomen, CA | 1 |
| Aslan, V | 1 |
| Entok, E | 1 |
| Mikołajczyk, K | 1 |
| Zaba, R | 1 |
| Walkowiak, B | 1 |
| Grzybowski, G | 1 |
| Samborski, W | 1 |
| Dahabreh, IJ | 2 |
| Giannouli, S | 2 |
| Zoi, C | 2 |
| Zoi, K | 2 |
| Voulgarelis, M | 2 |
| Moutsopoulos, HM | 1 |
| Sato, Y | 1 |
| Fukunaga, T | 1 |
| Hayashi, T | 1 |
| Asada, Y | 1 |
| Loukopoulos, D | 1 |
| Hendrick, A | 1 |
| Quiquandon, I | 1 |
| Claisse, JF | 1 |
| Capiod, JC | 1 |
| Delobel, J | 1 |
| Prin, L | 1 |
| Lombardi, C | 1 |
| Rusconi, C | 1 |
| Faggiano, P | 1 |
| Lanzani, G | 1 |
| Campana, C | 1 |
| Arbustini, E | 1 |
| Winn, RE | 1 |
| Kollef, MH | 1 |
| Meyer, JI | 1 |
| Esteve, J | 1 |
| Cervantes, F | 1 |
| Bosch, F | 1 |
| Cobo, F | 1 |
| Montserrat, E | 1 |
| Rozman, C | 1 |
| Metzler, B | 1 |
| Günther, E | 1 |
| Perier, P | 1 |
| Braun, B | 1 |
| Hust, MH | 1 |
| Demiroglu, H | 1 |
| Dündar, S | 1 |
| Fruhwald, FM | 1 |
| Aglas, F | 1 |
| Schumacher, M | 1 |
| Zweiker, R | 1 |
| Eber, B | 1 |
| Klein, W | 1 |
| Bletry, O | 1 |
| Díaz, F | 1 |
| Collazos, J | 1 |
| Means-Markwell, M | 1 |
| Burgess, T | 1 |
| deKeratry, D | 1 |
| O'Neil, K | 1 |
| Mascola, J | 1 |
| Fleisher, T | 1 |
| Lucey, D | 1 |
| Liozon, E | 1 |
| Soria, P | 1 |
| Gissot, V | 1 |
| Loustaud, V | 1 |
| Jauberteau, MO | 1 |
| Vidal, E | 1 |
| Rimbrot, S | 1 |
| Bennett, M | 1 |
| Komorovski, M | 1 |
| Levy, Y | 1 |
| Schaller, JL | 1 |
| Burkland, GA | 1 |
| Perkins, M | 1 |
| Watson, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| An Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Dexpramipexole (KNS-760704) in Subjects With Hypereosinophilic Syndrome[NCT02101138] | Phase 2 | 15 participants (Actual) | Interventional | 2014-03-14 | Active, not recruiting | ||
| Assessment of Glucocorticoid Responsiveness and Mechanisms of Resistance in Hypereosinophilic Syndromes[NCT01524536] | Phase 4 | 26 participants (Actual) | Interventional | 2012-02-16 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean baseline absolute eosinophil count in participants prior to initiation of glucocorticoids (NCT01524536)
Timeframe: Baseline (Day 1)
| Intervention | 10^3 cells per microliter (Geometric Mean) |
|---|---|
| Steroid Challenge - Glucocorticoid Responsiveness | 2.81 |
| Steroid Challenge - Glucocorticoid Suboptimal Responsiveness | 3.85 |
| Steroid Challenge - Glucocorticoid Unresponsiveness | 5.90 |
Mean baseline immunoglobulin E (IgE) level in participants prior to initiation of glucocorticoid (NCT01524536)
Timeframe: Baseline (Day 1)
| Intervention | IU/mL (Geometric Mean) |
|---|---|
| Steroid Challenge - Glucocorticoid Responsiveness | 285.2 |
| Steroid Challenge - Glucocorticoid Suboptimal Responsiveness | 1171.5 |
| Steroid Challenge - Glucocorticoid Unresponsiveness | 434.8 |
"Response to glucocorticoid challenge as assessed by the percentage of the eosinophil count 24 hours post-glucocorticoid challenge relative to the Baseline AEC for each participant.~Measure Description (%): Percent of baseline AEC is defined as the Absolute Eosinophil Count at 24 hours divided by the Absolute Eosinophil Count at Baseline *100." (NCT01524536)
Timeframe: 24 hours
| Intervention | percentage of eosinophil count (Mean) |
|---|---|
| Steroid Challenge - Responders | -69.6 |
| Steroid Challenge - Non-responders | -13.6 |
Cardiac involvement in participants with hypereosinophilic syndromes (HES) (NCT01524536)
Timeframe: Baseline (Day 1)
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroid Challenge - Glucocorticoid Responsiveness | 1 |
| Steroid Challenge - Glucocorticoid Suboptimal Responsiveness | 0 |
| Steroid Challenge - Glucocorticoid Unresponsiveness | 4 |
Participants with idiopathic hypereosinophilic syndromes (IHES) that achieved glucocorticoid responsiveness, suboptimal responsiveness, or without response. (NCT01524536)
Timeframe: Baseline (Day 1)
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroid Challenge - Glucocorticoid Responsiveness | 6 |
| Steroid Challenge - Glucocorticoid Suboptimal Responsiveness | 2 |
| Steroid Challenge - Glucocorticoid Unresponsiveness | 2 |
Participants with lymphoid hypereosinophilic syndromes (LHES) that achieved glucocorticoid responsiveness, suboptimal responsiveness, or without response. (NCT01524536)
Timeframe: Baseline (Day 1)
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroid Challenge - Glucocorticoid Responsiveness | 2 |
| Steroid Challenge - Glucocorticoid Suboptimal Responsiveness | 1 |
| Steroid Challenge - Glucocorticoid Unresponsiveness | 2 |
Participants with myeloid hypereosinophilic syndromes (MHES) that achieved glucocorticoid responsiveness, suboptimal responsiveness, or without response. (NCT01524536)
Timeframe: Baseline (Day 1)
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroid Challenge - Glucocorticoid Responsiveness | 0 |
| Steroid Challenge - Glucocorticoid Suboptimal Responsiveness | 0 |
| Steroid Challenge - Glucocorticoid Unresponsiveness | 1 |
Participants with overlap hypereosinophilic syndromes that achieved glucocorticoid responsiveness, suboptimal responsiveness, or without response. (NCT01524536)
Timeframe: Baseline (Day 1)
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroid Challenge - Glucocorticoid Responsiveness | 3 |
| Steroid Challenge - Glucocorticoid Suboptimal Responsiveness | 2 |
| Steroid Challenge - Glucocorticoid Unresponsiveness | 1 |
Pulmonary involvement in participants with hypereosinophilic syndromes (HES) (NCT01524536)
Timeframe: Baseline (Day 1)
| Intervention | Participants (Count of Participants) |
|---|---|
| Steroid Challenge - Glucocorticoid Responsiveness | 4 |
| Steroid Challenge - Glucocorticoid Suboptimal Responsiveness | 3 |
| Steroid Challenge - Glucocorticoid Unresponsiveness | 3 |
12 reviews available for hydroxyurea and Hypereosinophilic Syndrome
| Article | Year |
|---|---|
Hypereosinophilic syndromes in the precision medicine era: clinical, molecular aspects and therapeutic approaches (targeted therapies).
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Im | 2019 |
Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis.
Topics: Adrenal Cortex Hormones; Alemtuzumab; Antibodies, Monoclonal; Cyclosporine; Humans; Hydroxyurea; Hyp | 2021 |
World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Bone Marrow Examination; Clone Cells; Disease Manage | 2014 |
Management of Hypereosinophilic Syndromes.
Topics: Adrenal Cortex Hormones; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesy | 2015 |
Treatment of hypereosinophilic syndromes--the first 100 years.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Antigens, CD; Antigens, Neoplasm; Antiviral Agents | 2012 |
Idiopathic hypereosinophilic syndrome in children: 3 cases with review of literature.
Topics: Child, Preschool; Female; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Infant; Male; Retrospecti | 2013 |
Clinical management of the hypereosinophilic syndromes.
Topics: Adrenal Cortex Hormones; Antibodies; Benzamides; Enzyme Inhibitors; Humans; Hydroxyurea; Hypereosino | 2012 |
Idiopathic hypereosinophilic syndrome: a report of four cases in Arabs, and a review of the literature.
Topics: Adult; Anti-Inflammatory Agents; Arabs; Female; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Int | 2001 |
[Disorders with eosinophilia, treatment of hypereosinophilic syndrome].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Decision Trees; Eosinophilia; Glucocorti | 2005 |
Interferon treatment for hypereosinophilic syndromes and systemic mastocytosis.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Movement; Cell Prolifera | 2005 |
Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon.
Topics: Apoptosis; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Interferon-alpha; Interferon-gamma; Pred | 2007 |
[The eosinophil: doctor Jekyll or mister Hyde?].
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Eosinophils; Humans; Hydroxyurea; Hypereosinophilic | 1998 |
1 trial available for hydroxyurea and Hypereosinophilic Syndrome
| Article | Year |
|---|---|
Management of hypereosinophilic syndrome: a prospective study in the era of molecular genetics.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyto | 2007 |
34 other studies available for hydroxyurea and Hypereosinophilic Syndrome
| Article | Year |
|---|---|
[Hypereosinophilic syndromes].
Topics: Eosinophils; Glucocorticoids; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imatinib Mesylate | 2019 |
38-Year-Old Man With Asthma and Eosinophilia.
Topics: Adult; Anti-Asthmatic Agents; Antineoplastic Agents; Asthma; Diagnosis, Differential; Disease Progre | 2017 |
Image Gallery: A case of chronic eosinophilic leukaemia.
Topics: Aged; Antineoplastic Agents; Exanthema; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Leukemia; M | 2017 |
Eyelid Swelling and Subconjunctival Infiltration as Ophthalmic Manifestations in a Child with Idiopathic Hypereosinophilic Syndrome.
Topics: Child; Conjunctival Diseases; Drug Therapy, Combination; Edema; Enzyme Inhibitors; Eosinophils; Eyel | 2018 |
Hypereosinophilic syndrome in two cats.
Topics: Animals; Anti-Inflammatory Agents; Blood Cell Count; Cat Diseases; Cats; Fatal Outcome; Female; Hema | 2008 |
Images in cardiology. Cardiac magnetic resonance imaging in Löffler's endocarditis.
Topics: Biopsy, Needle; Bone Marrow; Chest Pain; Diagnosis, Differential; Drug Therapy, Combination; Endomyo | 2008 |
Success of short-term, higher-dose imatinib mesylate to induce clinical response in FIP1L1-PDGFRalpha-negative hypereosinophilic syndrome.
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Dose-Response Relationship, Drug | 2009 |
Cardiac tamponade: a rare complication of idiopathic hypereosinophilic syndrome.
Topics: Aged; Biopsy; Cardiac Tamponade; Echocardiography; Female; Humans; Hydroxyurea; Hypereosinophilic Sy | 2009 |
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibod | 2009 |
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibod | 2009 |
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibod | 2009 |
Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibod | 2009 |
Steroid-unresponsive hypereosinophilic syndrome.
Topics: Anti-Inflammatory Agents; Antineoplastic Agents; Benzamides; Child; Drug Therapy, Combination; Human | 2011 |
Chronic eosinophilic leukemia with erythroblastic proliferation and the rare translocation t(8;9)(p22;p24) with PCM1-JAK2 fusion gene: a distinct clinical, pathological and genetic entity with potential treatment target?
Topics: Antineoplastic Agents; Cell Proliferation; Chromosomes, Human, Pair 8; Chromosomes, Human, Pair 9; C | 2012 |
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate.
Topics: Alkylating Agents; Antimetabolites; Benzamides; Bone and Bones; Busulfan; Cladribine; Combined Modal | 2002 |
Eosinophilic leukemic transformation in polycythemia rubra vera (PRV).
Topics: Aged; Chromosome Aberrations; Cytogenetic Analysis; Humans; Hydroxyurea; Hypereosinophilic Syndrome; | 2005 |
[A 69-year-old man with deep fatigue, weight loss and eosinophilia].
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents; Diagnosis, Differential; Fatigue; Follow-Up St | 2005 |
Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benz | 2006 |
[Two patients with hypereosinophilic syndrome].
Topics: Adult; Benzamides; Diagnosis, Differential; Enzyme Inhibitors; Female; Humans; Hydroxyurea; Hypereos | 2006 |
Factor V Leiden mutation and deep venous thrombosis in a patient with hypereosinophilic syndrome.
Topics: Adult; Anticoagulants; Coumarins; Enzyme Inhibitors; Factor V; Heparin, Low-Molecular-Weight; Humans | 2006 |
[The hypereosinophilic syndrome: case report].
Topics: Adult; Benzamides; Bone Marrow; Diagnosis, Differential; Eosinophils; Humans; Hydroxyurea; Hypereosi | 2006 |
Hypereosinophilic syndrome associated with occlusive coronary thrombosis and right ventricular thrombus.
Topics: Adult; Coronary Angiography; Coronary Thrombosis; Coronary Vessels; Eosinophils; Fatal Outcome; Gluc | 2008 |
Hypereosinophilic syndrome: another face of janus?
Topics: Aged; Chronic Disease; Female; Flow Cytometry; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Janu | 2008 |
Psychosis during interferon in eosinophilic leukaemia.
Topics: Adolescent; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Combined Modali | 1994 |
alpha-Interferon and hypereosinophilic syndrome with trisomy 8: karyotypic remission.
Topics: Chromosomes, Human, Pair 8; Combined Modality Therapy; Female; Humans; Hydroxyurea; Hypereosinophili | 1995 |
Successful reduction of endomyocardial fibrosis in a patient with idiopathic hypereosinophilic syndrome. A case report.
Topics: Dipyridamole; Drug Therapy, Combination; Echocardiography, Doppler; Endomyocardial Fibrosis; Female; | 1995 |
Pulmonary involvement in the hypereosinophilic syndrome.
Topics: Adult; Critical Care; Female; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Male; Middle Aged; Pr | 1994 |
[Alpha interferon treatment in idiopathic hypereosinophilic syndrome resistant to conventional therapy].
Topics: Adult; Anti-Inflammatory Agents; Antineoplastic Agents; Drug Resistance, Multiple; Glucocorticoids; | 1996 |
[Löffler's parietal fibroplastic endocarditis. Echocardiographic course over 5 years].
Topics: Adult; Anti-Inflammatory Agents; Drug Therapy, Combination; Echocardiography, Transesophageal; Elect | 1997 |
Combination of interferon-alpha and hydroxyurea in the treatment of idiopathic hypereosinophilic syndrome.
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Int | 1997 |
Images in cardiovascular medicine. Löffler's endocarditis.
Topics: Anti-Inflammatory Agents; Echocardiography; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Male; M | 1998 |
Reversible cerebellar involvement in the idiopathic hypereosinophilic syndrome.
Topics: Aged; Cerebellar Diseases; Female; Glucocorticoids; Humans; Hydroxyurea; Hypereosinophilic Syndrome; | 1999 |
Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15.
Topics: Adult; Antineoplastic Agents; Dyspnea; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Interleukin- | 2000 |
[Horton's disease and hypereosinophilic syndrome: a non-fortuitous association].
Topics: Aged; Anti-Inflammatory Agents; Female; Giant Cell Arteritis; Glucocorticoids; Humans; Hydroxyurea; | 2000 |
[Eosinophilic ascites as a presenting symptom of the hypereosinophilic syndrome].
Topics: Adult; Ascitic Fluid; Asthma; Diagnosis, Differential; Eosinophilia; Humans; Hydroxyurea; Hypereosin | 2001 |
Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate.
Topics: Adult; Benzamides; Drug Therapy, Combination; Humans; Hydroxyurea; Hypereosinophilic Syndrome; Imati | 2001 |
Successful treatment of hypereosinophilic syndrome in a dog.
Topics: Animals; Anti-Inflammatory Agents; Dog Diseases; Dogs; Enzyme Inhibitors; Eosinophilia; Female; Hydr | 2001 |